- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07573631
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This Phase 2, multi-center, open-label extension study is designed to assess the long-term safety, tolerability, and functional efficacy of weekly intravenous doses of BMN 351 administered to participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping in the Phase 1/2 study, 351-201. Up to 18 participants ages 4 through 23 at baseline will enroll in the trial after completing 351-201.
The first visit for this study is the same as the final visit of 351-201. To be eligible for this study, potential participants must satisfy the eligibility criteria described in the protocol.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Italy
-
Milan, Italy, Italien
- Fondazione Serena ETS - Centro Clinico NeMO Milano
-
Rome, Italy, Italien
- UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
-
-
-
-
Netherlands
-
Leiden, Netherlands, Nederländerna, 2333 ZA
- Leids Universitair Medisch Centrum
-
-
-
-
Spain
-
Seville, Spain, Spanien, 41013
- Hospital Viamed Santa Angela De la Cruz
-
-
-
-
United Kingdom
-
London, United Kingdom, Storbritannien, WC1N 3JH
- Great Ormond Street Hospital NHS Foundation Trust
-
-
-
-
Turkey
-
Istanbul, Turkey, Turkiet (Türkiye)
- Yeditepe University Kosuyolu Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Participants must have completed 351-201 without permanent discontinuation of the investigational medicinal product (IMP) or withdrawal from the study
Currently receiving treatment with oral corticosteroids, on a stable dose regimen during 351-201, and must remain on a consistent dose regimen throughout 351-202 or 351-203 except for modifications to accommodate changes in weight
- Transition to the equivalent dose of vamorolone is permitted in 351-202 where approved in participating countries.
- Willing and able to adhere to the study visit schedule and other protocol requirements
Willing to use contraception (sexually mature males) throughout the study and for 90 days after the final dose, if sexually active
- Contraceptive use by males should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Willing and able to provide written assent (if required by local regulations or the IRB/IEC) after the nature of the study has been explained and prior to performance of any research-related procedure
- Willing and able to provide written, signed informed consent as parent or guardian after the nature of the study has been explained and prior to performance of any research-related procedure
Exclusion Criteria:
- Have known coagulation disorder
Are taking any prohibited medications
- any approved exon skipping therapy within 12 weeks prior to baseline or with any gene therapy for the treatment of DMD at any time
- anti-coagulants, anti-thrombotics, or anti-platelet agents
- immunosuppressants
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: BMN 351
Participants from 351-201 enrolling in 351-202 will initially receive BMN 351 at the dose level at which they completed 351-201.
Once all 351-201 participants have completed their Week 25 visit in 351-202, available safety and PD data will be analyzed and a single optimal dose level will be selected for 351-202.
All participants from 351-201 will transition to that dose level at their next applicable visit.
|
Anti-sense Oligonucleotide BMN 351 will be administered intravenously
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To assess the long-term safety and tolerability of BMN 351 in participants with DMD
Tidsram: Through study completion, at least 1 year
|
The safety and tolerability of BMN 351 will be assessed based on the incidence of adverse and serious adverse events.
|
Through study completion, at least 1 year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To evaluate the effect of BMN 351 on physical function
Tidsram: Change from baseline and subsequent 24-week incremental visits
|
Timed 4 stair climb (4SC) will be assessed at the specified visits and compared to individual baseline and external controls
|
Change from baseline and subsequent 24-week incremental visits
|
|
To evaluate the effect of BMN 351 on physical function
Tidsram: Change from baseline and subsequent 24-week incremental visits
|
SV95C will be assessed at the specified visits and compared to individual baseline and external controls
|
Change from baseline and subsequent 24-week incremental visits
|
|
To evaluate the effect of BMN 351 on physical function
Tidsram: Change from baseline and subsequent 24-week incremental visits
|
PUL 2.0 will be assessed at the specified visits and compared to individual baseline and external controls
|
Change from baseline and subsequent 24-week incremental visits
|
|
To evaluate the effect of BMN 351 on physical function
Tidsram: Change from baseline and subsequent 24-week incremental visits
|
North Star Ambulatory Assessment (NSAA) will be assessed at the specific visits and compared to individual baseline and external controls
|
Change from baseline and subsequent 24-week incremental visits
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To evaluate the trough plasma concentration of BMN 351
Tidsram: Baseline, Week 13, Week 25, Week 37, Week 49
|
Serial predose measurements of trough plasma PK
|
Baseline, Week 13, Week 25, Week 37, Week 49
|
|
To evaluate the immune response to BMN 351
Tidsram: Change from baseline and subsequent 24-week incremental visits
|
Anti-BMN 351 antibodies and Anti-dystrophin antibodies
|
Change from baseline and subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
Tidsram: Change from baseline to subsequent 24-week incremental visits
|
Forced Expiratory Volume in 1 second (FEV1) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
Tidsram: Change from baseline to subsequent 24-week incremental visits
|
Forced Vital Capacity (FVC) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
Tidsram: Change from baseline to subsequent 24-week incremental visits
|
Peak Cough Flow (PCF) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
Tidsram: Change from baseline to subsequent 24-week incremental visits
|
Maximal Inspiratory Pressure (MIP) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
|
To evaluate lung function longitudinally for participants ages 7 and above
Tidsram: Change from baseline to subsequent 24-week incremental visits
|
Maximal Expiratory Pressure (MEP) for participants ages 7 and above
|
Change from baseline to subsequent 24-week incremental visits
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 351-202
- 2024-511656-41-00 (Ctis)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .